0
Lung Cancer |

Low Prevalence of High Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study FREE TO VIEW

Alain Tremblay; Niloofar Taghizadeh; Paul MacEachern; David Stather; Annette McWilliams; Kam Soghrati; Kazuhiro Yasufuku; David Hwang; Serge Puksa; Kayvan Amjadi; Harmanjatinder Sekhon; Simon Martel; Francis Laberge; Christian Couture; Michael Johnston; Ming Tsao; Diana Ionescu; Sukhinder Atkar-Khattra; Stephen Lam; Stefan Urbanski; Jean-Claude Cutz; Zhaolin Xu; Martin Tammemagi
Author and Funding Information

Division of Respiratory Medicine, University of Calgary and Alberta Thoracic Oncology Program, Calgary, AB, Canada; Fionna Stanley Hospital and Sir Charles Gairdner Hospital,Perth, WA, Australia; Princess Margaret Cancer Centre, Toronto, ON, Canada; The Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval, QC, Canada; Université Laval, Laval, QC, Canada; Beatrice Hunter Cancer Research Institute and Dalhousie University, Halifax, NS, Canada; University Health Network and Princess Margaret Cancer Centre, Toronto, ON, Canada; The British Columbia Cancer Agency, Vancouver, BC, Canada; University of Calgary, Foothills Cancer Centre, Calgary, AB, Canada; McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Brock University, St. Catherines, ON, Canada


Chest. 2015;148(4_MeetingAbstracts):547A. doi:10.1378/chest.2266025
Text Size: A A A
Published online

Abstract

SESSION TITLE: Lung Cancer Diagnosis

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Wednesday, October 28, 2015 at 02:45 PM - 04:15 PM

PURPOSE: Lung cancer screening with low-dose chest tomography (LDCT) has been demonstrated to reduce mortality from this disease. Preliminary reports have suggested that up to 1 out of 5 lung cancers may be CT occult but detectable via autofluorescence bronchoscopy (AFB) which is known to improve the sensitivity for detection of preinvasive lesions in the central airway. We evaluated the prevalence of CT occult invasive and high grade preinvasive lesions in high risk subjects undergoing both AFB and LDCT screening for lung cancer.

METHODS: 2,537 subjects who had 2% or greater lung cancer risk over 3 years using a risk prediction tool were recruited from 8 centers across Canada in the Pan-Canadian Early Detection of Lung Cancer Study (2008-2011). The first half of these subjects received AFB in addition to CT (n=1300). We determined the prevalence of CT and AFB abnormalities and analyzed the association between selected predictor variables and dysplasia and carcinoma in situ (CIS) lesions, using univariate and multivariate logistic regression models.

RESULTS: Among 1300 subjects who underwent AFB, a total of 776 endobronchial biopsies were performed in 333 (25.6%) subjects. Dysplastic or higher grade lesions were detected in 5.2 % of the subjects [n=68; mild dysplasia (n=36), moderate dysplasia (n=25), severe dysplasia (n=3), CIS (n=1), carcinoma (n=3)]. Fifty six prevalence lung cancers were detected by LDCT. No invasive lung cancers were CT occult, although one case of CIS and 3 high grade pre-neoplastic lesions were detected by AFB alone. In the univariate models, significant risk factors for the presence of dysplastic (any grade) lesions or CIS included: lung cancer risk index; male gender; weight; and pack-years. In the fully adjusted model, male gender [Odd Ratio (OR) (95% CI)] 3.49 (1.50-8.13), pack-years 1.01 (1.00-1.03), and weight 1.02 (1.00-1.05) were significant independent predictors of dysplasia/CIS lesions.

CONCLUSIONS: Application of AFB in addition to LDCT in a high lung cancer risk cohort does not lead to an increased lung cancer detection rate.

CLINICAL IMPLICATIONS: Broad use of AFB as a screening tool in subjects at high risk of lung cancer does not appear justified given our findings and an overall decrease in the prevalence of squamous cell carcinoma.

DISCLOSURE: The following authors have nothing to disclose: Alain Tremblay, Niloofar Taghizadeh, Annette McWilliams, Paul MacEachern, David Stather, Kam Soghrati, Serge Puksa, Kazuhiro Yasufuku, Kayvan Amjadi, Simon Martel, Francis Laberge, Michael Johnston, Ming Tsao, Diana Ionescu, Stefan Urbanski, David Hwang, Jean-Claude Cutz, Harmanjatinder Sekhon, Christian Couture, Zhaolin Xu, Martin Tammemagi, Sukhinder Atkar-Khattra, Stephen Lam

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543